SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Podestà, M. Articles by Bacigalupo, A. Search for Related Content PubMed PubMed Citation Articles by Podestà, M. Articles by Bacigalupo, A. Related Collections Hematopoiesis and Stem Cells Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 91 No. 6 (March 15), 1998: pp. 1959-1965 The Assessment of the Hematopoietic Reservoir After Immunosuppressive Therapy or Bone Marrow Transplantation in Severe Aplastic Anemia By Marina Podestà, Giovanna Piaggio, Francesco Frassoni, Anna Pitto, Panagiotis Zikos, Mario Sessarego, Monica Abate, Maria Teresa Van Lint, Giovanni Berisso, and Andrea Bacigalupo From Divisione Ematologia 2, Ospedale S. Martino, Genova, Italy; and Laboratorio Citogenetica, DIMI, Università degli Studi, Genova, Italy.     ABSTRACT Abstract Introduction Methods Results Discussion References We investigated the hematopoietic reservoir in 43 severe aplastic anemia (SAA) patients following immunosuppression (IS) (n = 15) or bone marrow transplantation (BMT) (n = 28), at a median interval of 5 years (range, 2-20) from treatment. All patients had normal blood counts, good marrow cellularity, and normal numbers of colony forming unit-granulocyte macrophages (CFU-GM). Burst forming unit-erythroid (BFU-E) and colony forming unit-granulocyte erythroid megakaryocyte macrophages (CFU-GEMM) numbers were reduced when compared with normal controls. However, the most pronounced defect was observed at the level of long-term culture-initiating cells (LTC-IC), which significantly differed from controls (P < .00001) both for IS and BMT patients. Their number did not improve with time and was not affected by transplant or treatment-related variables. When IS patients were compared with BMT we found comparable numbers of CFU-GEMM (P = .8) and LTC-IC (P = .9), but lower numbers of BFU-E and CFU-GM (P = .05 and P = .004, respectively), suggestive of a persistent suppressive mechanism. These data indicate that LTC-IC numbers are severely reduced in BMT and IS patients, contradicting the common belief that the former are fully reconstituted as compared with the latter. In addition, the number of mature cells and committed progenitors does not seem to reflect the real size of the hematopoietic reservoir and few stem cells may be sufficient to guarantee normal hematopoiesis long term.     INTRODUCTION Abstract Introduction Methods Results Discussion References A STEM CELL DEFECT has been considered for a long time to be the major pathogenetic mechanism resulting in bone marrow failure in patients with severe aplastic anemia (SAA). Early studies using clonogenic cultures demonstrated either a lack or a marked reduction of all types of hematopoietic progenitor cells.1-4 Hematopoietic failure in these patients was also associated with a significant reduction of bone marrow mononuclear cells, phenotypically defined as CD34+ cells and with a lower plating efficiency in comparison with controls.5 These assumptions have been the basis for transplant procedures with syngeneic6 or allogeneic7 normal stem cells considered to be the only curative treatment for this disease. However, hematologic recovery in 50% to 80% of patients following immunosuppression (IS) with anti-lymphocyte-globulin (ALG), cyclosporine A (CyA) with or without growth factors,8-13 suggested the possibility that residual stem cells are present in SAA patients and that aplasia may be the result of a toxic or an immune-mediated effect.14,15 Patients recovering after IS therapy exhibit for many years reduced formation of hematopoietic colonies, reduced responsiveness to stem cell factor (SCF) of CD34+ cells, and a decreased survival time in vitro in the presence of FLT3 ligand16,17 despite good marrow cellularity and normal blood counts. The long-term culture initiating cells (LTC-IC) assay, which is considered the best surrogate method for assessing hematopoietic stem cells allows us to enumerate them with good approximation. The primitive progenitors can be separated, in humans, from the clonogenic compartment with respect to a number of physical and antigenic properties. In the mouse, these progenitor cells can form colonies in vitro with preservation of both their long-term and competitive repopulating ability.18,19 In SAA patients the frequency of these progenitors is markedly reduced when compared with normal controls both using cobblestone area forming cell (CAFC)20 or LTC-IC assays.21 Qualitatively, LTC-IC are also abnormal, showing a profoundly reduced clonogenic capacity that reflects a defect in the supply of mature progenitors from a more primitive cell compartment.21 Both these points may be explained by the concept that stem cell numbers are limited in SAA. In fact, in transplanted mice, the proportion of clones actively contributing to hematopoiesis increases in relation to the size of the donor inoculum and the premature recruitment into mitotic cycle may have a negative effect on the proliferative capacity of stem cell pool.22 This study is an attempt to quantify the hematopoietic reservoir in SAA patients long after IS treatment or allogeneic bone marrow transplantation (BMT), by testing for differences among the two groups of patients in terms of early and committed progenitors.     MATERIALS AND METHODS Abstract Introduction Methods Results Discussion References Patients Forty-three SAA patients entered this study: 28 received an unmanipulated HLA-matched sibling transplant, and 15 underwent IS therapy. Transplanted patients.   There were 18 males and 10 females; median age was 21 years (range, 7 to 36); two patients (UPN 91 and UPN 638) received marrow from a twin. Patients were infused with a median of 4.1 × 108 mononuclear cells (MNC)/kg (range, 2.0 to 10.4) and 6.0 × 104 colony forming unit-granulocyte macrophage (CFU-GM)/kg (range, 2.4 to 24: data recovered on 13/28 patients) (Table 1). Recipients were prepared for transplant with cyclophospamide (Cy) 200 mg/kg body weight; they did not receive prophylactic growth factors after BMT. Median time from transplant was 5 years (range, 2 to 20).   View this table: [in this window] [in a new window]   Table 1. Bone Marrow Transplant Patients IS patients.   There were 11 males and 4 females; median age was 26 years (range, 13 to 53). Each patient received IS therapy as described in Table 2; all of them were transfusion independent. Median time from diagnosis was 6 years (range, 2 to 18).   View this table: [in this window] [in a new window]   Table 2. Immunosuppressive Therapy Controls Thirty heparinized marrow samples were obtained from allogeneic donors providing marrow for transplantation, in order to supply both control studies and layers for LTC-IC assay. All donors gave their informed consent. Forty-three long-term survivors after allogeneic BMT (median interval, 6 years; range, 2 to 15) were also tested for in vitro growth. This group of patients consisted of 15 chronic myelogenous leukemia (CML) and 28 acute leukemia (AL) that were prepared for transplant with Cy followed by total body irradiation (TBI). Cytogenetics Cytogenetic analysis and standard GTG or QFQ-banding techniques were performed in each case according to standard methods.23 Flow Cytometry Analysis For the measurement of the expression of GPI-anchored molecules two monoclonal antibodies (MoAb) were used: mouse anti-human PE-conjugated CD14 MoAb (Leu2; Becton Dickinson, Mountain View, CA) with FITC-labeled CD16 Fc-gamma receptor type III (Becton Dickinson). Clonogenic Assays Bone marrow mononuclear cells were isolated by centrifugation on 1,077 g/mL Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden) to eliminate the majority of erythrocytes, granulocytes, and platelets. The cells were then washed twice in Iscove's modified Dulbecco's medium (IMDM; MA Product, Walkersville, MD) containing 5% fetal calf serum (FCS; Hyclone, Logan, UT) and resuspended in the same medium. 105 MNC were plated in 1.1 mL semisolid culture medium consisting of IMDM supplemented with antibiotics (penicillin/streptomycin, GIBCO, Grand Island, NY), 0.9% methylcellulose (Sigma, St Louis, MO), 30% FCS, 1% crystallized bovine serum albumin (Sigma), 104 mol/L mercaptoethanol (2ME, Sigma, final concentration) recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) (10 ng) (Genzyme Corporation, Cambridge, MA), rhIL3 (50 ng) (Sandoz International, Basel CH), rhG-CSF (10 ng) (Hoffman-La Roche, Wyhlen, Germany), and 4U erythropoietin (Genzyme). After 14 days of incubation in a humidified atmosphere at 37°C and 5% CO2, colonies (CFU-GM, BFU-E, and CFU-GEMM) were classified and counted in the same dish using an inverted microscope. LTC-IC Aliquots of mononuclear marrow cells (usually 3 × 106 MNC/well) were placed in triplicate in 6 well tissue culture dishes (A/S NUNC, Milano) over a murine irradiated cell line (M2-10B4, kindly provided by Dr C. Eaves).24 LTC-IC were maintained for 3 days at 37°C, then switched to 33°C and fed weekly by replacement of half of the growth medium: IMDM + 12.5% FCS + 12.5% Horse Serum (GIBCO) + 10-4 mol/L ME (final concentration) + 106 mol/L hydrocortisone-21-hemisuccinate (HC, Sigma, final concentration) + 0.016 mmol/L folic acid (Sigma, final concentration) containing half of the nonadherent cells with fresh growth medium. After 5 weeks, adherent cells were trypsinized and combined with the nonadherent fraction; these cells were then washed and assayed for their CFC content as described above. Limiting Dilution Assay The absolute number of LTC-IC was determined using a limiting dilution technique to calculate their proliferative potential.25 Briefly, irradiated murine stromal cells were seeded into 96-well flat-bottomed trays; the following day, four dilutions of cells were added to each of 96 wells (total volume 200 µL). A minimum of 12 replicates for each dilution was performed. Cultures were fed at weekly intervals for 5 weeks, then they were overlaid with semisolid culture medium and growth factors as described above. After 18 to 20 days of incubation, wells were examined for the presence of colonies. The frequency of LTC-IC and the mean number of colonies per positive well were calculated by determining the cell dilution that resulted in 37% negative wells, equivalent to single hit kinetics (1 LTC-IC/well) according to the Poisson distribution. The clonogenic capacity of a single LTC-IC also was calculated by dividing the numbers of colonies derived from bulk cultures by the frequency of LTC-IC.26,27 Statistical Analysis Statistical analyses were carried out using a Student's t-test (NCSS package, J.L. Hintze, Kaysville, UT).     RESULTS Abstract Introduction Methods Results Discussion References At the time of our study all patients were leading a normal life with a Karnowsky score between 80% and 100% and no requirement for blood transfusions. Clinical Data Peripheral blood counts were stable and within normal range in the two groups. Mean WBC numbers were, respectively, for BMT patients 6.9 ± 0.3 × 109/L and 5.6 ± 0.4 × 109/L for IS patients (P = .3). Differential counts were normal and not different in the two groups (BMT, neutrophils 54.2% ± 2.8%, lymphocytes 36.5% ± 2.0%; IS, neutrophils 51.8% ± 2.4%, lymphocytes 36% ± 2.2%). Hematocrit and hemoglobin levels were, respectively, for BMT, 41.5% ± 1.1%-14 ± 0.4 g/dL and for IS, 40.8% ± 1.2%14 ± 0.5 g/dL (P = .1 and P = .3). Platelet counts were significantly higher in patients who underwent BMT (213 ± 12 v 143 ± 12 × 109/L, P = .001) but both values were within normal range (Fig 1).Marrow cellularity ranged between 20% and 100% (median 90%); the three hematologic lineages were well represented and maturation was also normal. Eight of 15 IS patients had evidence of PIG-deficient clones in at least two consecutive determinations. All patients had a normal karyotype at the time of our observations. View larger version (16K): [in this window] [in a new window]   Fig 1. Hematopoietic reconstitution in bone marrow transplant (BMT = white bars) and immunosuppression (IS = dark bars) patients. All parameters were within normal range. WBC are expressed × 109/L; PMN are expressed as percentage; Ly are expressed as percentage; platelets (Pt) are expressed × 109/L; hematocrit (HT) is expressed as percentage, hemoglobin (Hb) is expressed g/dL; P values represent differences between BMT and IS patients. () BMT; () IS. Controls Median laboratory standards were (normal controls, 30): CFU-GM = 58/105 MNC (range, 35 to 198); BFU-E = 12/105 MNC (range, 7 to 34); CFU-GEMM = 3/105 MNC (range, 0 to 10); LTC-IC = 34/106 MNC (range, 15 to 238). BMT Patients BMT patients grew normal numbers of CFU-GM (P = .5), while significant differences were observed for BFU-E: median 6 (range, 0 to 32) (P = .02) and CFU-GEMM, median 0 (range, 0 to 12) (P = .004) when compared with controls. The reduction of LTC-IC frequency was still more pronounced: median 2 (range, 0 to 16) (P < .00001) (Table 3).   View this table: [in this window] [in a new window]   Table 3. Transplanted Patients Graft versus host disease (GvHD) did not influence the number of LTC-IC: patients who had experienced mild or limited acute and chronic GvHD did not have larger numbers of LTC-IC when compared with patients with severe GvHD (P = .5 in both cases). Cytomegalovirus (CMV) infection also did not seem to affect LTC-IC frequency (P = .5). The cell dose also had no apparent influence; there was no difference in LTC-IC for patients receiving more or less than 4.1 × 108/kg MNC (P = .2) and more or less than 6.0 × 104/kg CFU-GM (P = .4), cut-offs being the median value. In order to assess whether defective reservoir may be due to underlying disease or to transplant procedure, we also tested 44 long-term survivors transplanted for other malignancies. This group of patients showed the same number of CFU-GM (60 ± 6.2, P = .3) and BFU-E (8.8 ± 0.7, P = .6) than SAA patients. Moreover, similar defective number of CFU-GEMM (1.1 ± 0.3, P = .1) and LTC-IC (2.9 ± 0.6, P = .3) were observed. IS Patients CFU-GM numbers were within the normal range (P = .4) but the numbers of BFU-E (median, 0; range, 0 to 39) and CFU-GEMM (median, 0; range, 0 to 3) were significantly lower than in controls (P = .0005 and P = .002). A severe deficiency was observed at the LTC-IC level (median, 1; range, 0 to 23) (P < .00001) Table 4.   View this table: [in this window] [in a new window]   Table 4. IS Patients IS Versus BMT Patients When we compared the in vitro growth of IS and BMT patients we observed no difference in CFU-GEMM and LTC-IC numbers (P = .8 and P = .9). However, late progenitors were significantly higher in BMT patients (CFU-GM, P = .004; BFU-E, P = .05). Limiting Dilution Studies In our lab each LTC-IC from normal marrow produced a median of 3.0 CFCs (range, 1 to 16) detectable after 5 weeks of culture (no. 12 cases, data not shown). To investigate whether transplanted patients and IS responders had a qualitatively different population, we plated bone marrow cells in limiting dilution as previously described. In transplanted patients (no. 10 cases tested) the median number of CFC derived from each LTC-IC was 3.0 (range, 1.1 to 10), not significantly different from normal controls (P = .2). IS responders (no. 6 cases tested) showed a number of secondary colonies derived from one LTC-IC ranging between 1.0 and 3.3 (median 2.0) that were significantly different from controls (P < .05). Effect of Time on Hematopoietic Progenitors The frequencies of CFU-GM and LTC-IC (expressed as percentage of expected growth) were then stratified in different points to study the effect of time elapsed from transplant or from IS therapy on late hematopoietic reconstitution. In IS patients CFU-GM number showed a slow but uniform improvement up to the normal range, which was permanently reached (Fig 2); transplanted patients instead reached and maintained normal values earlier in the first 2 years after transplant (Fig 2). LTC-IC showed the same pattern in the two groups of patients: percentage of expected growth remained far below controls (<10%) and did not improve with time. Two IS patients (no. 217-2809 and no. 217-2945) were studied at different times. Hematologic values were unmodified and within normal range at each time point. The first (217-2809) showed constant low colony formation of both early and late progenitors. The second (217-2945) presented an unexpected normal number of LTC-IC (57.8/106 MNC) at the time of an abnormal karyotype (20%: 45X,-Y); BFU-E and CFU-GEMM did not grow. In the following two observations the abnormal clone disappeared (46XY) from the marrow and the LTC-IC number fell to the value expected for aplastic patients. At the same time consistent numbers of BFU-E and CFU-GEMM appeared into the culture. View larger version (13K): [in this window] [in a new window]   Fig 2. Effect of time on growth pattern of clonogenic (CFU-GM) and early progenitors (LTC-IC). Patients have been grouped on the basis of treatment (IS or BMT) and time elapsed from. CFU-GM (GM) and LTC-IC (LTC) numbers are expressed as percentage of expected growth; 100% means median laboratory standards (CFU-GM = 58/105 MNC; LTC-IC = 34/106 MNC). y = years from treatment. () IS; () BMT.     DISCUSSION Abstract Introduction Methods Results Discussion References This study demonstrates a severe and long lasting reduction of LTC-IC in the marrow of SAA patients transplanted either from HLA identical siblings or syngeneic twins and in IS responders. In both groups LTC-IC number did not improve with time and were not affected by transplant or treatment-related variables. On the other hand, all SAA patients maintained stable peripheral blood counts, good marrow cellularity and CFU-GM within normal range. Extremely low LTC-IC numbers, persisting for up to 20 years, may be explained by defective or limited amplification of the stem cell compartment due to the ability of the early hematopoietic progenitors "to count" their divisions and to regulate the production of clonogenic and mature cells when they have reached normal values.28,29 In this way stem cells may protect themselves from exhaustion due to a persistent proliferative stimulus and may allow self-renewal mechanism to take place. The cell dose and CFU-GM content of the graft did not influence the late hematopoietic reservoir. However, it has been pointed out that a higher degree of stem cell amplification is obtained in the mouse with the smallest number of stem cells transplanted, even though this is insufficient to achieve a comparable level of regeneration of stem cell population by comparison with its size in unperturbed animals.30 On the other hand, recovery of mature blood cell production in vivo may activate negative feedback regulatory mechanism to prematurely limit stem cell self-renewal ability. Other transplant-related variables (CMV infections, GvHD) did not apparently influence late hematopoietic reconstitution. IS patients had GEMM and LTC-IC frequency not different from transplanted patients but they grew lower number of BFU-E and CFU-GM and had lower platelet counts. These results are in keeping with the fact that proliferative potential of LTC-IC in our SAA patients was below normal. On the other hand, early progenitors may express an intrinsic dysfunction and may give rise only to a limited progeny.31 The different behavior of the two hematopoietic compartments (CFU-GM, LTC-IC) is more evident considering the growth patterns at different times following treatment (BMT or IS). Both groups of patients maintained similar LTC-IC frequency at very low level (10% expected growth) for the entire duration of our observation. The same number of early progenitors, however, gave rise to a progeny of different sizes, in fact in BMT patients clonogenic progenitors reached and maintained normal values within the first 2 years. Instead, IS responders showed a defective CFU-GM growth (20%-40% expected growth) up to 5 years following therapy. Beyond 6 years, CFU-GM numbers were similar in IS and BMT patients, suggesting that the observed growth pattern may be the consequence of a persistent suppressive mechanism limiting the expansion of clonogenic cells, still present a long time after response to therapy. This is in keeping with relapses occurring at discontinuation of CyA in IS patients.32 A persistent suppressive mechanism, associated with a reduced stem cell pool, may also explain late clonal evolution in some SAA patients. In fact, 8 of 15 completely reconstituted patients after immunosuppressive therapy had PIG-negative cells in the blood and one patient (no. 217-2945) occasional karyotypic abnormalities. On the other hand, patients who underwent transplant never developed abnormal clones, suggesting that a reduced stem cell pool does not necessarily imply "stressed hematopoiesis" nor abnormalities of the hematopoietic system. Then, an additional event, such as direct cytotoxic insult to stem cell22 or long-lasting suppression may favor clonal hematologic diseases. It should be also pointed out that the assay used (LTC-IC) may be unsuitable for the detection and quantification of early progenitors in SAA, thus giving an underestimate of the residual stem cell pool. In fact, one cannot exclude that in SAA patients, stem cells may be kept out of cycle by means of persistent immune-mediated suppression, and this may actually protect them from exhaustion due to excessive proliferation and differentiation. If this is the case, we would detect only early progenitors that have escaped this process without being able to quantify the real size of such population. Patient no. 217-2945 shows a very interesting pattern of growth; when a cytogenetic abnormality appeared (45X,-Y; 20%) he grew normal number of LTC-IC. This indicates that the LTC-IC compartment of SAA patients may expand as a response to the proliferation of abnormal cell clone; we have observed the same phenomenon in CML in cytogenetic relapse after allogeneic BMT (data not shown). Therefore, the number of early progenitors in SAA may be higher than determined with this assay, or alternatively the ability of LTC-IC to expand may be greater than expected. In keeping with this hypothesis is the fact that mobilized early progenitors greatly exceed in numbers the prediction based on steady state bone marrow analysis.33 Hematologic reconstitution in SAA, whether after BMT or IS, is a process involving a limited number of stem cells that first repopulate marrow spaces and then maintain hematopoiesis long-term. In transplanted patients reconstitution occurs rapidly and the persistent defect at the early progenitor cell level is almost completely masked if only clonogenic cells are evaluated. In IS responders clonogenic growth is defective for many years following therapy despite normal blood counts, possibly due to the continuous effect of a suppressive mechanism. In both cases small numbers of LTC-IC can maintain stable hematopoiesis, suggesting that stem cells are largely in excess under normal conditions and only few of them are active throughout a life time.     FOOTNOTES    Submitted May 20, 1997; accepted November 7, 1997.    Supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milano.    Address reprint requests to Marina Podestà, Biol Sci, Divisione Ematologia 2, Ospedale S. Martino, Largo R. Benzi 10, 16132-Genova, Italy.    The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.     REFERENCES Abstract Introduction Methods Results Discussion References 1. Hara H, Kai S, Fushimi M, Taniwaki S, Okatama T, Ohe Y, Fujita S, Naguchi K, Seuba M, Hamani H, Kanamasu A, Nagai K: Pluripotent haemopoietic precursors in vitro (CFU-mix) in aplastic anemia. Exp Hematol 8:1165, 1980[Medline] [Order article via Infotrieve] 2. Bacigalupo A, Podestà M, Raffo MR, Piaggio G, Vimercati R, Risso M, Marmont AM: Lack of in vitro colony formation and myelosuppressive activity in patients with severe aplastic anemia after autologous hematologic reconstitution. Exp Hematol 8:795, 1980[Medline] [Order article via Infotrieve] 3. Kern P, Heimpel H, Heit W, Kubanek B: Granulocytic progenitor cells in aplastic anemia. Br J Haematol 35:613, 1977[Medline] [Order article via Infotrieve] 4. Scopes J, Bagnara M, Gordon-Smith EC, Ball SE, Gibson FM: Haemopoietic progenitor cells are reduced in aplastic anemia. Br J Haematol 86:427, 1994[Medline] [Order article via Infotrieve] 5. Maciejewski JP, Anderson S, Katevas P, Young NS: Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br J Haematol. 87:227, 1994 6. Champlin RE, Feig SA, Sparkes RS, Gale RP: Bone marrow transplantation from identical twins in the treatment of aplastic anemia: Implications for the pathogenesis of the disease. Br J Haematol 56:455, 1984[Medline] [Order article via Infotrieve] 7. Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP, Rappeport JM, Storb R: Severe aplastic anemia: A prospective study of the effect of early marrow transplantation on acute mortality. Blood 48:63, 1976[Abstract/Free Full Text] 8. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavanchar A, Vogt HG, Herrmann F, Freund M, Meusers P, Salama A, Heimpel H: Treatment of aplastic anemia with antithymocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 324:1297, 1991[Abstract] 9. Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, Locatelli F, Mori PG, Saracco P, Todeschini A, Coser P, Iacopino P, Van Lint MT, Gluckman E: Antilymphocyte globulin, cyclosporin and granulocyte stimulating factor in patients with severe aplastic anemia (SAA): A pilot study of the EBMT SAA working party. Blood 85:1348, 1995[Abstract/Free Full Text] 10. Doney K, Leisenring W, Storb R, Appelbaum FR: Primary treatment of acquired aplastic anemia: Outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med 126:107, 1997[Abstract/Free Full Text] 11. Paquette R, Tebyani N, Frane M, Ireland P, Ho WG, Champlin RE, Nimer SD: Long term outcome of aplastic anemia in adults treated with antithymocyte globulin: Comparison with bone marrow transplantation. Blood 85:283, 1995[Abstract/Free Full Text] 12. Rosenfeld SJ, Kimball J, Vining D, Young NS: Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 85:3058, 1995[Abstract/Free Full Text] 13. Speck B, Gluckman E, Haak HL, van Rood JJ: Treatment of aplastic anemia by antilymphocyte globulin with and without allogeneic bone marrow infusions. Lancet 2:1145, 1977[Medline] [Order article via Infotrieve] 14. Young NS, Barrett AJ: The treatment of severe acquired aplastic anemia. Blood 85:3367, 1995[Free Full Text] 15. Kagan WA, Ascensao JA, Pahwa RN, Hansen JA, Goldstein G, Valera EB, Incefy GS, Moore MAS, Good RA: Aplastic anemia: Presence in human bone marrow of cells that suppress myelopoiesis. Proc Natl Acad Sci USA 73:2890, 1976[Abstract/Free Full Text] 16. Wodnar-Filipowics A, Yancik S, Moser Y, dalle Carbonare V, Gratwohl A, Tichelli A, Speck B, Nissen C: Levels of soluble stem cell factor in serum of patients with aplastic anemia. Blood 81:3259, 1983[Abstract/Free Full Text] 17. Wodnar-Filipowicz A, Manz CY, Schklovskaya A, Slanicka Krieger M, Gratwohl A, Tichelli A, Speck B, Nissen C: Tyrosine kinase receptors and their ligands in aplastic anemia, in Gluckman, E Coulombel L (eds): Ontogeny in Hematopoiesis. Aplastic Anemia, vol 235. Colloque INSERM. Paris, France, John Libbey Eurotext, 1995, p 223 18. Frazer CC, Szilvassi SJ, Eaves CJ, Humpries RK: Proliferation of totipotent hematopoietic stem cells in vitro with retention of long-term competitive in vivo reconstituting ability. Proc Natl Acad Sci USA 89:1968, 1992[Abstract/Free Full Text] 19. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ: Functional characterization of individual human hemopoietic stem cells cultured at limiting dilution on supportive stromal layer. Proc Natl Acad Sci USA 84:3584, 1992 20. Schrezenmeir H, Gerok M, Heimpel H, Raghavanchar A: Use of limiting dilution type long-term marrow cultures in frequency analysis of haemopoietic stem cells in aplastic anemia. European Bone Marrow Transplant 18th Annual Meeting, Stockholm, Sweden, 201a, 1992 (abstr) 21. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS: A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture initiating cells) in acquired aplastic anemia. Blood 88:1983, 1996[Abstract/Free Full Text] 22. Young NS: The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. Blood 79:1385, 1992[Free Full Text] 23. Podestà M, Piaggio G, Frassoni F, Sessarego M, Benvenuto F, Pitto A, Vassallo F, Soracco M, Ferrero R, Carella AM: Very primitive hemopoietic cells (LTC-IC) are present in Philadelphia-negative cytaphereses collected during early recovery after chemotherapy for chronic myelogenous leukemia. Bone Marrow Transplant 16:548, 1995 24. Lemoine FM, Humpries RK, Abraham SDM, Krystal G, Eaves CJ: Partial characterization of a novel stromal cell-derived preB-cell growth factor active on normal and immortalized preB cells. Exp Hematol 16:718, 1988[Medline] [Order article via Infotrieve] 25. Sutherland HJ, Lansdorp PM, Henkelmann DH, Eaves AC, Eaves CJ: Functional characterization of individual human hemopoietic stem cells cultured at limiting dilution on supportive stromal layer. Proc Natl Acad Sci USA 84:3584, 1992 26. Taswell C: Limiting dilution assays for the determination of immunocompetent cell frequencies: I. Data analysis. J Immunol 126:1614, 1981[Abstract] 27. Porter EH, Berry RJ: The efficient design of transplantable tumor assays. J Cancer 17:583, 1963 28. de Haas G, Nijhof W, Van Zant G: Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: Correlation between lifespan and cycling activity. Blood 5:1543, 1997 29. Rosendaal M, Hodgson GS, Bradly TR: Organization of haemopoietic stem cells: The generation-age hypothesis. Cell Tissue Kinetics 12:17, 1979[Medline] [Order article via Infotrieve] 30. Pawliuk R, Eaves C, Humphries EK: Evidence of both ontogeny and transplant dose-regulated expansion of hematopoietic stem cells in vivo. Blood 88:2852, 1996[Abstract/Free Full Text] 31. Scopes J, Daly S, Atkinson R, Ball SE, Gordon-Smith EC, Gibson FM: Aplastic anemia: Evidence for dysfunctional bone marrow progenitor cells and the corrective effect of granulocyte colony-stimulating factor in vitro. Blood 87:3179, 1996[Abstract/Free Full Text] 32. Marsh JCW, Sociè G, Schrezenmeier H, Tichelli A, Gluckman E, Ljungman P, McCann SR, Raghavachar A, Marin P, Hows JM, Bacigalupo A(null): Haemopoietic growth factors in aplastic anemia: A cautionary note. The Lancet 344:172, 1994[Medline] [Order article via Infotrieve] 33. Eaves CJ: Peripheral blood stem cells reach new heights. Blood 82:1957, 1993[Free Full Text] © 1998 by The American Society of Hematology.   0006-4971/98/91-0012$3.00/0 CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: N. Sessarego, A. Parodi, M. Podesta, F. Benvenuto, M. Mogni, V. Raviolo, M. Lituania, A. Kunkl, G. Ferlazzo, F. D. Bricarelli, et al. Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application Haematologica, March 1, 2008; 93(3): 339 - 346. [Abstract] [Full Text] [PDF] A. Bacigalupo Aplastic Anemia: Pathogenesis and Treatment Hematology, January 1, 2007; 2007(1): 23 - 28. [Abstract] [Full Text] [PDF] W. Zeng, A. Miyazato, G. Chen, S. Kajigaya, N. S. Young, and J. P. Maciejewski Interferon-{gamma}-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles Blood, January 1, 2006; 107(1): 167 - 175. [Abstract] [Full Text] [PDF] F. Frassoni, M. Podesta, R. Maccario, G. Giorgiani, G. Rossi, M. Zecca, A. Bacigalupo, G. Piaggio, and F. Locatelli Cord blood transplantation provides better reconstitution of hematopoietic reservoir compared with bone marrow transplantation Blood, August 1, 2003; 102(3): 1138 - 1141. [Abstract] [Full Text] [PDF] M. Engelhardt, J. Finke, N. Rufer, T. H. Brummendorf, B. Chapuis, C. Helg, P. M. Lansdorp, and E. Roosnek Does telomere shortening count? Blood, August 1, 2001; 98(3): 888 - 890. [Full Text] [PDF] T. H. Brummendorf, J. P. Maciejewski, J. Mak, N. S. Young, and P. M. Lansdorp Telomere length in leukocyte subpopulations of patients with aplastic anemia Blood, February 15, 2001; 97(4): 895 - 900. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Podestà, M. Articles by Bacigalupo, A. Search for Related Content PubMed PubMed Citation Articles by Podestà, M. Articles by Bacigalupo, A. Related Collections Hematopoiesis and Stem Cells Social Bookmarking                   What's this?

	Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020